Finally, this study demonstrates, through analysis of real-world clinical samples, the upregulation of the IFNG and STAT3 pathways, elucidating the potential of PD-L1 as a biomarker for patients with EGFR-mutant NSCLC undergoing first-line osimertinib therapy (Figure 7). This evidence concerns the gene STAT3 and non-small cell lung carcinoma.